Hematopoietic Stem Cell Transplantation
Conditions
Keywords
Microbial DNA/RNA, Hematopoietic stem cell transplant (HSCT)
Brief summary
Infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplant (HSCT). The purpose of this study is to evaluate if metagenomic next-generation sequencing (mNGS) can detect microbial signatures in people undergoing HSCT, and if microbial identification can be correlated with clinical features of infection (e.g., fever). Participants undergoing HSCT as part of other studies at the NIH Clinical Center (CC) will provide blood before the transplant and through 6 months after. Total nucleic acid will be extracted from plasma and subjected to mNGS. The primary objective of this study is to investigate if by using plasma and an mNGS approach, we can detect bacterial, fungal, protozoan, or viral DNA/RNA over time, in immunocompromised patients undergoing transplantation. Secondary objectives are to: (1) To correlate microbial identification with episodes of fever or clinical suspicion of infection; and to (2) correlate change in microbial signatures in patients with suspected immune reconstitution inflammatory syndrome. The study is conducted at the NIH Clinical Center. Participants, aged 3 years and older, on other research studies at the NIH CC who are undergoing HSCT are invited to take part of this study. Expected participation is up to six months.
Detailed description
Study Description: Infections are a major cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplant (HSCT). The purpose of this study is to evaluate if metagenomic next-generation sequencing (mNGS) can detect microbial signatures in people undergoing HSCT, and if microbial identification can be correlated with clinical features of infection (e.g., fever). Participants undergoing HSCT as part of other studies at the NIH Clinical Center (CC) will provide blood before the transplant and through 6 months after. Total nucleic acid will be extracted from plasma and subjected to mNGS. Objectives: Primary: To investigate if by using plasma and an mNGS approach, we can detect bacterial, fungal, protozoan, or viral DNA/RNA over time, in immunocompromised patients undergoing transplantation. Secondary: 1. To correlate microbial identification with episodes of fever or clinical suspicion of infection. 2. To correlate change in microbial signatures in patients with suspected immune reconstitution inflammatory syndrome. Endpoints: Primary: Comparison of mNGS results to routine clinical test results (microbiology and/or pathology) Secondary: 1. Calculation of frequencies of different microbial identifications as it relates to the development of fever or microbiologically/clinically defined infection. 2. Changes in different microbial signatures over time
Interventions
None listed
Sponsors
National Institutes of Health Clinical Center (CC)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
3 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study; an individual must meet all the following criteria: 1. Male or female, aged 3 years or older. 2. Co-enrolled on another study at the NIH CC, under which they will undergo HSCT. 3. Stated willingness to comply with all study procedures and availability for the duration of the study. 4. Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
Exclusion criteria
An individual with any condition that, in the opinion of the investigator, contraindicates participation in this study, will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Any positive clinical results for each of 5 pathogen categories | Six months | Research blood draw at screening, during fever episodes and at follow up days 30, 100 and 180 (+/- 7 days). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORRose A Lee, M.D.
National Institutes of Health Clinical Center (CC)
Outcome results
None listed